2 / 20
Page 19
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
New biomarkers for prognosis of aggressive prostate cancer
Carlos S Moreno
Emory University, USA
A
large number of men are diagnosedwith prostate cancer each
year, but many will not experience morbidity or mortality as a
result of their cancers. Therefore, biomarkers for prostate cancer
are necessary to carefully select patients for initial diagnostic
biopsy or to facilitate care decisions for men who have already
been diagnosed with prostate cancer. RNA-based approaches to
biomarker discovery allow the investigation of non-coding RNAs,
gene fusion transcripts, splice variants and multi-gene expression
panels in tissue, urine or blood as opportunities to improve care
decisions. In an effort to identify biomarkers of recurrence, we
performed global RNA sequencing on 106 formalin-fixed, paraffin-
embedded (FFPE) prostatectomy samples from 100 patients
at three independent sites, defining a 24-gene signature panel
(Sig24). The 24 genes in this panel have functions in cell cycle
progression, angiogenesis, hypoxia, apoptosis, PI3K signaling,
steroid metabolism, translation, chromatin modification and
transcription. In our validation study, patients with high Sig24
scores had an increased risk of developing metastasis (HR: 3.78,
95% CI: 1.96-7.29, p<0.001) or experiencing prostate cancer
specificmortality (PCSM) (HR: 6.54, 95%CI: 2.16-19.83, p<0.001) in
an independent validation case cohort set of 235patients fromthe
MayoClinic. Thefindingsof this studydemonstratetheapplicability
of Sig24 for the prognosis of metastasis or PCSM following radical
prostatectomy. Future studies investigating the combination of
Sig24with available prognostic tests may provide new approaches
to improve risk stratification for patients with prostate cancer.
Speaker Biography
Carlos S Moreno is Associate Professor of Pathology and Laboratory Medicine and Biomedical
Informatics at Emory University, where he is a Member of the Winship Cancer Institute in
the Cancer Genetics and Epigenetics Program. He has obtained his BS and MS in Aeronautics
and Astronautics from MIT and worked for NASA before he earned his PhD in Genetics and
Molecular Biology from Emory University in 1998. He specializes in Cancer Bioinformatics and
Cancer Genomics and his laboratory has used whole genome expression analysis and next-
generation sequencing to identify biomarkers of aggressive disease in prostate cancer.
e:
cmoreno@emory.edu